Evidence map›Paper›PMID 39759558›Full record

ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2024

Can the reprogrammed cancer cells serve as an alternative source of (induced) cancer stem cells?

Ewelina Stelcer, Małgorzata Blatkiewicz, Karol Jopek, Wiktoria Maria Suchorska, Marcin Rucinski

Abstract read
In one paragraph

Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ewelina StelcerDepartment of Histology and Embryology, Poznan University of Medical Sciences, Poznan, Poland.
Małgorzata BlatkiewiczDepartment of Histology and Embryology, Poznan University of Medical Sciences, Poznan, Poland.
Karol JopekDepartment of Histology and Embryology, Poznan University of Medical Sciences, Poznan, Poland.
Wiktoria Maria SuchorskaDepartment of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland.
Marcin RucinskiDepartment of Histology and Embryology, Poznan University of Medical Sciences, Poznan, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cancer stem cells (CSCs) constitute a small and elusive subpopulation of cancer cells within a tumor mass and are characterized by stem cell properties. Reprogrammed CSCs exhibit similar capability to initiate tumor growth, metastasis, and chemo- and radio-resistance and have similar gene profiles to primary CSCs. However, the efficiency of cancer cell reprogramming remained relatively low. There is limited literature available on the reprogramming of lung cancer cells. Hence, in this study we have conducted reprogramming of human lung cancer cells towards more benign type of cells. Materials and methods: The reprogramming process was carried out with the use of STEMCCA vector. We have investigated the gene expression profile of induced CSCs (iCSCs) using the microarray technique. Results: The lung iCSCs demonstrate morphology characteristics of induced pluripotent stem cells (iPSCs) and gene expression profile that significantly differ from cells before reprogramming. We have also presented the elevated level of expression of genes associated with the cancer stemness and thus revealed new interesting CSC-like molecular markers. Conclusions: These preliminary results demonstrated that the reprogramming process

Indexed as

cancer stem cellsgene expression profilenon-small cell lung cancerreprogramming

Identifiers

PMID39759558
PMCPMC11698551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.